111 related articles for article (PubMed ID: 37029589)
21. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
22. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
23. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
25. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
28. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Wang C; Sallman DA
Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg E; Tobiasson M; Greenberg P
Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
[TBL] [Abstract][Full Text] [Related]
31. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
32. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
33. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
34. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
Randall MP; DeZern AE
Cancer J; 2023 May-Jun 01; 29(3):152-159. PubMed ID: 37195771
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of lower risk myelodysplastic syndromes].
Park S
Bull Cancer; 2023 Nov; 110(11):1156-1161. PubMed ID: 37500385
[TBL] [Abstract][Full Text] [Related]
36. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Volpe VO; Komrokji RS
Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
